AR092555A1 - 2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc - Google Patents
2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del sncInfo
- Publication number
- AR092555A1 AR092555A1 ARP130103279A ARP130103279A AR092555A1 AR 092555 A1 AR092555 A1 AR 092555A1 AR P130103279 A ARP130103279 A AR P130103279A AR P130103279 A ARP130103279 A AR P130103279A AR 092555 A1 AR092555 A1 AR 092555A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- cycloalkyl
- halogen
- pyridinyl
- indoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
2-oxo-2,3-dihidro-indoles de la fórmula general (1) en la que: el hexágono N¹ es fenilo o un grupo heteroarilo elegido entre piridinilo, pirimidinilo, imidazolilo, isoxazolilo y pirazolilo; el hexágono N² es fenilo o piridinilo, pero el átomo de N del grupo piridinilo puede ocupar cualquiera de las posiciones libres; R¹ es hidrógeno, alquilo inferior, alquilo inferior sustituido por halógeno, alcoxi inferior o halógeno; n es el número 1 ó 2; si n es el número 2, R¹ puede ser el mismo o no; R²/R² son con independencia entre sí alquilo inferior o junto con el átomo de carbono, al que están unidos, forman un anillo cicloalquilo C₃₋₆; R³ es alquilo inferior, cicloalquilo C₃₋₆, CH₂-cicloalquilo C₃₋₆, cicloalquilo C₃₋₆ en el que un átomo de carbono del anillo se ha reemplazado por -O-, (CH₂)₃-O-cicloalquilo C₃₋₆, alquilo inferior sustituido por hidroxi, alquilo inferior sustituido por halógeno, (CH₂)₃-S(O)₂-cicloalquilo C₃₋₆ o (CH₂)₂-S(O)₂-alquilo inferior; R⁴ es hidrógeno, halógeno o alquilo inferior; m es el número 1 ó 2; si m es el número 2, R⁴ puede ser igual o no; así como a sus sales farmacéuticamente aceptables, a una mezcla racémica, a sus enantiómeros correspondientes y/o isómeros ópticos y/o estereoisómeros. Estos compuestos son útiles en el tratamiento de enfermedades del SNC.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12184249 | 2012-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092555A1 true AR092555A1 (es) | 2015-04-22 |
Family
ID=47044777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130103279A AR092555A1 (es) | 2012-09-13 | 2013-09-13 | 2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc |
Country Status (23)
Country | Link |
---|---|
US (1) | US9221816B2 (es) |
EP (1) | EP2895476B1 (es) |
JP (1) | JP6116693B2 (es) |
KR (1) | KR101706877B1 (es) |
CN (1) | CN104619701B (es) |
AR (1) | AR092555A1 (es) |
AU (1) | AU2013314417B2 (es) |
BR (1) | BR112015005186A2 (es) |
CA (1) | CA2883817C (es) |
CL (1) | CL2015000559A1 (es) |
CR (1) | CR20150084A (es) |
EA (1) | EA027176B1 (es) |
ES (1) | ES2590531T3 (es) |
HK (1) | HK1206721A1 (es) |
IL (1) | IL237266A0 (es) |
MA (1) | MA37943B1 (es) |
MX (1) | MX2015003330A (es) |
PE (1) | PE20150943A1 (es) |
PH (1) | PH12015500400A1 (es) |
SG (1) | SG11201501923WA (es) |
TW (1) | TWI490213B (es) |
WO (1) | WO2014040969A1 (es) |
ZA (1) | ZA201501262B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2915536C (en) * | 2013-06-19 | 2021-10-19 | F. Hoffmann-La Roche Ag | Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives |
EP3145923B1 (en) | 2014-05-22 | 2019-01-30 | F. Hoffmann-La Roche AG | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives |
CA2950475C (en) * | 2014-06-26 | 2022-08-30 | F. Hoffmann-La Roche Ag | Indolin-2-one or pyrrolo-pyridin-2-one derivatives |
CN108137561B (zh) | 2015-11-06 | 2021-03-26 | 豪夫迈·罗氏有限公司 | 二氢吲哚-2-酮衍生物 |
PE20181885A1 (es) | 2015-11-06 | 2018-12-07 | Hoffmann La Roche | Derivados de indolin-2-ona |
EP3371169B1 (en) | 2015-11-06 | 2019-07-17 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives for use in the treatment of cns and related disorders |
JP6857651B2 (ja) | 2015-11-06 | 2021-04-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Cns疾患の処置に有用なインドリン−2−オン誘導体 |
CN106065008B (zh) * | 2016-06-16 | 2018-06-05 | 黑龙江中医药大学 | 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用 |
GB201709456D0 (en) * | 2017-06-14 | 2017-07-26 | Ucb Biopharma Sprl | Therapeutic agents |
WO2023250064A1 (en) * | 2022-06-23 | 2023-12-28 | Biogen Ma Inc. | Tyrosine kinase 2 inhibitors and uses thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3417643A1 (de) | 1984-05-12 | 1985-11-14 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte |
GR851085B (es) | 1984-05-12 | 1985-11-25 | Boehringer Mannheim Gmbh | |
DE3445669A1 (de) | 1984-12-14 | 1986-06-19 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US4835280A (en) | 1985-01-18 | 1989-05-30 | Boehringer Mannheim Gmbh | Indoline compounds for synthesis of pharmaceutically active pyrrolobenzimidazoles |
DE3501497A1 (de) | 1985-01-18 | 1986-07-24 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte |
DE3803775A1 (de) | 1988-02-09 | 1989-08-17 | Boehringer Mannheim Gmbh | Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
DE3818830A1 (de) | 1988-06-03 | 1989-12-14 | Boehringer Mannheim Gmbh | Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel |
DE3925584A1 (de) | 1989-08-02 | 1991-02-07 | Boehringer Mannheim Gmbh | Neue n-(dimethyloxophosphinylmethyl-)-lactame, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
JP2002522452A (ja) | 1998-08-04 | 2002-07-23 | スージェン・インコーポレーテッド | 蛋白質キナーゼの調節剤3−メチリデニル−2−インドリノン |
JP2002540096A (ja) | 1999-03-24 | 2002-11-26 | スージェン・インコーポレーテッド | キナーゼ阻害剤としてのインドリノン化合物 |
CN100562513C (zh) * | 2003-06-12 | 2009-11-25 | 安斯泰来制药有限公司 | 苯甲酰胺衍生物或其盐 |
MXPA05013434A (es) * | 2003-06-12 | 2006-03-17 | Astellas Pharma Inc | Derivados de benzamida o sal del mismo. |
BRPI0518192B8 (pt) | 2004-10-20 | 2021-05-25 | Applied Res Systems Ars Holding N V | derivados de 3-arilamino piridina, seu uso e seu processo de fabricação, e composição farmacêutica |
US20060142247A1 (en) | 2004-12-17 | 2006-06-29 | Guy Georges | Tricyclic heterocycles |
CN101312720A (zh) | 2005-11-30 | 2008-11-26 | 安斯泰来制药有限公司 | 2-氨基苯甲酰胺衍生物 |
CA2695071A1 (en) * | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | The use of benzamide derivatives for the treatment of cns disorders |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
WO2010123139A1 (ja) * | 2009-04-24 | 2010-10-28 | 持田製薬株式会社 | スルファモイル基を有するアリールカルボキサミド誘導体 |
JP6063870B2 (ja) * | 2010-11-08 | 2017-01-18 | ライセラ・コーポレイション | RORγ活性の阻害用のN−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療 |
-
2013
- 2013-09-10 MX MX2015003330A patent/MX2015003330A/es unknown
- 2013-09-10 CA CA2883817A patent/CA2883817C/en not_active Expired - Fee Related
- 2013-09-10 CN CN201380047631.2A patent/CN104619701B/zh active Active
- 2013-09-10 EA EA201590438A patent/EA027176B1/ru not_active IP Right Cessation
- 2013-09-10 BR BR112015005186A patent/BR112015005186A2/pt not_active IP Right Cessation
- 2013-09-10 AU AU2013314417A patent/AU2013314417B2/en not_active Ceased
- 2013-09-10 SG SG11201501923WA patent/SG11201501923WA/en unknown
- 2013-09-10 PE PE2015000365A patent/PE20150943A1/es not_active Application Discontinuation
- 2013-09-10 WO PCT/EP2013/068668 patent/WO2014040969A1/en active Application Filing
- 2013-09-10 ES ES13759241.6T patent/ES2590531T3/es active Active
- 2013-09-10 JP JP2015531533A patent/JP6116693B2/ja active Active
- 2013-09-10 EP EP13759241.6A patent/EP2895476B1/en active Active
- 2013-09-10 KR KR1020157009290A patent/KR101706877B1/ko active IP Right Grant
- 2013-09-12 TW TW102133020A patent/TWI490213B/zh not_active IP Right Cessation
- 2013-09-13 AR ARP130103279A patent/AR092555A1/es unknown
-
2015
- 2015-02-16 IL IL237266A patent/IL237266A0/en unknown
- 2015-02-19 CR CR20150084A patent/CR20150084A/es unknown
- 2015-02-24 PH PH12015500400A patent/PH12015500400A1/en unknown
- 2015-02-24 ZA ZA2015/01262A patent/ZA201501262B/en unknown
- 2015-03-06 CL CL2015000559A patent/CL2015000559A1/es unknown
- 2015-03-11 US US14/645,033 patent/US9221816B2/en active Active
- 2015-03-20 MA MA37943A patent/MA37943B1/fr unknown
- 2015-07-27 HK HK15107160.2A patent/HK1206721A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EA027176B1 (ru) | 2017-06-30 |
CA2883817A1 (en) | 2014-03-20 |
CN104619701B (zh) | 2016-10-19 |
TW201416358A (zh) | 2014-05-01 |
US9221816B2 (en) | 2015-12-29 |
KR101706877B1 (ko) | 2017-02-15 |
JP2015529673A (ja) | 2015-10-08 |
ZA201501262B (en) | 2016-03-30 |
HK1206721A1 (en) | 2016-01-15 |
JP6116693B2 (ja) | 2017-04-19 |
MX2015003330A (es) | 2015-06-05 |
PE20150943A1 (es) | 2015-06-20 |
CR20150084A (es) | 2015-04-06 |
EP2895476A1 (en) | 2015-07-22 |
TWI490213B (zh) | 2015-07-01 |
MA37943A1 (fr) | 2016-04-29 |
SG11201501923WA (en) | 2015-04-29 |
KR20150054991A (ko) | 2015-05-20 |
US20150284386A1 (en) | 2015-10-08 |
EP2895476B1 (en) | 2016-06-22 |
CN104619701A (zh) | 2015-05-13 |
CA2883817C (en) | 2017-09-05 |
AU2013314417B2 (en) | 2016-01-21 |
BR112015005186A2 (pt) | 2017-07-04 |
PH12015500400A1 (en) | 2015-04-27 |
CL2015000559A1 (es) | 2015-07-10 |
AU2013314417A1 (en) | 2015-03-05 |
EA201590438A1 (ru) | 2015-06-30 |
IL237266A0 (en) | 2015-04-30 |
ES2590531T3 (es) | 2016-11-22 |
MA37943B1 (fr) | 2016-11-30 |
WO2014040969A1 (en) | 2014-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092555A1 (es) | 2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc | |
CO2017011174A2 (es) | Derivados de etileno como moduladores metabotropicos de receptores de glutamato | |
AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
AR105668A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
PE20180233A1 (es) | Nuevos compuestos biciclicos como inhibidores duales de atx / ca | |
PE20181197A1 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
PE20151446A1 (es) | Peptidos como agonistas de oxitocina | |
UY33910A (es) | 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC | |
UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
AR099047A1 (es) | Derivados etinilo | |
PE20141556A1 (es) | Derivados de etinilo como moduladores alostericos de mglur5 | |
AR086036A1 (es) | DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5) | |
PE20170427A1 (es) | Peptidos como agonistas de la oxitocina | |
AR097721A1 (es) | Derivados de etinilo | |
AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
MX2016008536A (es) | Derivados de fluoro-naftilo. | |
AR105662A1 (es) | Derivados de piridina y de pirimidina como inhibidores del eaat3 | |
UY35393A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
CR20130476A (es) | Derivados de pirazolidin-3-ona | |
AR073794A1 (es) | Derivados heterociclicos de triazinas sustituidas, medicamentos que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento del alzheimer y otro tipo de demencias. | |
AR103952A1 (es) | Derivados de pirimidina-diona | |
CR20150143A (es) | Derivados de etinilo como moduladores del receptor de actividad mglur5 | |
AR107490A1 (es) | Derivados de pirazol-piridina como inhibidores de eaat3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |